Full history for every metric is available with a Kvantra account
IRRAS AB (publ) (IRRAS.ST)
Key financial summary
Financials in SEK| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | SEK m | 12 | 6 | 5 | 7 | 22 | 40 | 43 |
| Operating profit | SEK m | -168 | -197 | |||||
| Net profit | SEK m | -61 | -139 | -151 | -136 | -136 | -167 | -195 |
| EPS reported | SEK | -0.52 | -0.42 | |||||
| Operating cashflow per share | SEK | -0.55 | -0.55 | |||||
| Capex per share | SEK | 0.01 | 0.01 | |||||
| FCF per share | SEK | -0.56 | -0.56 | |||||
| Free cash flow | SEK m | -179 | -193 | |||||
| Net debt | SEK m | -70 | -13 | |||||
| Book value equity | SEK m | 146 | 43 | |||||
| Book value per share | SEK | 0.46 | 0.05 | |||||
| Number of shares | m | 320.54 | 794.81 | |||||
| DPS (TTM paid) | SEK | 0.00 | 0.00 |
Financial summary
Financials in SEK| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.03 | 4.22 | |||||
| P/S LTM | x | 3.77 | 4.22 | |||||
| P/FCF LTM | x | -0.84 | -0.94 | |||||
| EV/EBITDA LTM | x | -0.59 | -0.90 | |||||
| EV/Sales LTM | x | 2.20 | 3.91 | |||||
| Earnings Yield LTM | % | -110.40% | -324.19% | |||||
| FCF Yield | % | -118.80% | -106.29% | |||||
| Quality | ||||||||
| ROE | % | -114.08% | -129.31% | |||||
| ROIC | % | -110.30% | -110.30% | |||||
| Operating margin | % | -420.25% | -420.25% | |||||
| Gross margin | % | 20.91% | 20.91% | |||||
| FCF/Sales | % | -448.22% | -448.22% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +78.67% | +36.45% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -28.26 | -1,931.79 | |||||
| Net Debt/EBITDA | x | 0.42 | 0.42 | |||||
| EBIT/Net interest | x | -602.47 | -602.47 | |||||
| Net debt/market cap | % | -46.55% | -7.21% | |||||
| Net debt/Equity | x | -0.48 | -0.30 | |||||
| Gross debt/equity | x | 0.04 | 0.00 | |||||
Company overview
IRRAS AB (publ), a medical technology company established in 2011 and headquartered in Stockholm, Sweden, is dedicated to developing medical solutions that enhance the lives of critically ill patients globally. The firm specializes in neurocritical care products, aiming to transform patient outcomes and address complexities inherent in current treatment methods. Among its offerings is IRRAflow, an advanced irrigating intracranial drainage system that integrates controlled drainage, automated irrigation, and continuous intracranial pressure (ICP) monitoring, used effectively for treating hemorrhagic strokes and chronic subdural hematoma. Additionally, IRRAS provides the Hummingbird ICP monitoring system, comprising the HICP200 Control Module and various catheters like the H610 for quad ICP monitoring with drainage and the H110 for solo ICP monitoring. These Hummingbird neuromonitoring tools are vital for managing patients with elevated ICP caused by conditions such as traumatic brain injury, subarachnoid hemorrhage, and strokes. The company distributes its products to hospitals through both its direct sales force and a network of strategic distribution partners.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
IRRAS AB (publ) (IRRAS.ST)
IRRAS AB (publ), a medical technology company established in 2011 and headquartered in Stockholm, Sweden, is dedicated to developing medical solutions that enhance the lives of critically ill patients globally. The firm specializes in neurocritical care products, aiming to transform patient outcomes and address complexities inherent in current treatment methods. Among its offerings is IRRAflow, an advanced irrigating intracranial drainage system that integrates controlled drainage, automated irrigation, and continuous intracranial pressure (ICP) monitoring, used effectively for treating hemorrhagic strokes and chronic subdural hematoma. Additionally, IRRAS provides the Hummingbird ICP monitoring system, comprising the HICP200 Control Module and various catheters like the H610 for quad ICP monitoring with drainage and the H110 for solo ICP monitoring. These Hummingbird neuromonitoring tools are vital for managing patients with elevated ICP caused by conditions such as traumatic brain injury, subarachnoid hemorrhage, and strokes. The company distributes its products to hospitals through both its direct sales force and a network of strategic distribution partners.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free